Two potential U.S. product approvals for Vyzulta(TM)1 (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE2 (cetirizine ophthalmic solution) 0.24% expected in 2017 Strong pipeline including two products poised to enter in Phase 2 clinical trials Significant reduction in future fixed costs Cash position of €28.9 million as of December 31, 2016
March 31, 2017 - Sophia Antipolis, France - Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial and operating results for the year ended December 31, 2016, as approved by the Board of Directors on March 29, 2017, and provided an overview of its milestones and activities.
